Benitec Biopharma Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses), averaging +11.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q3 FY26 | $-0.27 | $-0.24 | +11.1% | Beat |
Back to BNTC overview · BNTC holders · BNTC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.